MRK Stock Price - Merck & Co. Inc. Stock Quote (U.S.: NYSE) - MarketWatch

Open $55.00
Day Range 54.56 - 55.29
52 Week Range 52.83 - 66.41
Market Cap $143.87B
Shares Outstanding 2.7B
Public Float 2.69B
Beta 0.83
Rev. per Employee $579.44K
P/E Ratio 63.85
EPS $0.86
Yield 3.50%
Dividend $0.48
Ex-Dividend Date Mar 14, 2018
Short Interest 22.19M 03/15/18
% of Float Shorted 0.82%
Average Volume 13.03M

5 Day	1.71%
1 Month	-0.64%
3 Month	-3.14%
YTD	-2.23%
1 Year	-12.09%

MarketWatch
Other Dow Jones

Merck's stock jumps 3.3% to pace the 28 of 30 Dow components trading higher

Apr. 9, 2018 at 9:34 a.m. ET
by Tomi Kilgore

Merck's stock climbs 2.3% to pace Dow's premarket gainers after positive trial news

Apr. 9, 2018 at 9:13 a.m. ET
by Tomi Kilgore

Merck's stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytruda as monotherapy for the first-line treatment of metastatic non-small cell lung cancer. The primary endpoint was overall survival. An independent data monitoring committee (DMC) determined that treatment with Keytruda resulted in significantly longer overall survival than platinum-based chemotherapy in tested patients. Based on the DMC's finding, the trial will continue to evaluation progression-free survival, which is the secondary endpoint. Merck's stock has lost 5.2% year to date through Monday, while the SPDR Health Care Select Sector ETF has shed 3.4% and the Dow Jones Industrial Average has slipped 3.2%.

Apr. 9, 2018 at 7:00 a.m. ET
by Tomi Kilgore

Merck's stock up 1.5% premarket after Keytruda trial meets primary endpoint

Apr. 9, 2018 at 6:52 a.m. ET
by Tomi Kilgore

Here are Friday’s worst stocks as trade conflict and a weak jobs report disappoint investors

Apr. 7, 2018 at 3:50 p.m. ET
by Philip van Doorn

Stock market ends sharply lower on renewed trade war fears

Apr. 6, 2018 at 4:35 p.m. ET
by Barbara Kollmeyer

NewLink will review clinical programs after Merck, Incyte trial failure

NewLink Genetics Corp. plans to review its clinical programs after the failure of a similar drug in a Merck and Incyte clinical trial. NewLink noted that the mechanism of its drug, an IDO pathway inhibitor called indoximod, was different from other such products but said that it will nonetheless conduct a clinical program review because of the Incyte news. NewLink shares plummeted nearly 45% in Friday trade after Merck and Incyte said a trial testing their two drugs in combination did not meet its primary endpoint and that they are stopping the trial. NewLink shares have dropped nearly 55% over the last three months to $4.09, compared with a 5.4% drop in the S&P 500 .

Apr. 6, 2018 at 3:14 p.m. ET
by Emma Court

NewLink says its IDO inhibitors are different but will still conduct clinical program review

Apr. 6, 2018 at 3:04 p.m. ET
by Emma Court

NewLink Genetics plans to review clinical programs after Merck, Incyte trial failure

Apr. 6, 2018 at 3:03 p.m. ET
by Emma Court

NewLink Genetics shares plummet 39% after Merck, Incyte trial failure

NewLink Genetics Corp. shares plummeted 39.2% in premarket trade Friday after Merck and Incyte Corp. said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. NewLink has focused its research and development on IDO as a target for its cancer drugs, and its two lead therapies -- indoximod and NLG802 -- target the IDO pathway. The phase 3 trial tested Incyte's epacadostat, which is an IDO inhibitor, in combination with Merck's Keytruda, and was seen as an important trial for the entire IDO class of drugs. However, the combination did not improve progression-free survival for patients as compared with Keytruda alone, Merck and Incyte said on Friday, and the companies are stopping the trial. Drug companies have made big investments in these types of combination treatments, betting that pairing them will boost effectiveness, though Friday's trial results may undermine the theory. Bristol-Myers Squibb, another company that has invested in the IDO space, had shares decline 0.6% premarket. NewLink shares have dropped 18.7% over the last three months, compared with a 2.9% drop in the S&P 500 .

Apr. 6, 2018 at 9:14 a.m. ET
by Emma Court

Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Shares of Incyte Corp. plunged 19% in premarket trade Friday, and Merck & Co. Inc.'s stock dropped 1.9%, after the companies said an external data monitoring committee (eDMC) determined that results from a phase 3 study evaluating Incyte's epacadostat with Merck's Keytruda in patients with metastatic melanoma did not meet the primary endpoint of improving progression-free survival. Incyte's stock had been halted until 8 a.m. ET for news. The companies said the second primary endpoint of overall survival was also not expected to reach statistical significance. The companies said they decided to stop the study based on the eDMC's recommendation. "While we are disappointed that this study did not confirm the efficacy of epacadostat in combination with KEYTRUDA in patients with unresectable or metastatic melanoma, data from ECHO-301/KEYNOTE-252, including analyses of an extensive biomarker panel, will contribute to our understanding of the role of IDO1 inhibition in combination with PD-1 antagonists, and may inform our broader epacadostat clinical development program," said Incyte's Chief Medical Officer Steven Stein. Incyte's stock had shed 16.8% over the past three months through Thursday, while Merck shares had lost 4.3% and the Dow Jones Industrial Average had slipped 3.1%.

Apr. 6, 2018 at 8:04 a.m. ET
by Tomi Kilgore

Incyte shares fall 19% after resuming trade following a halt

Apr. 6, 2018 at 8:01 a.m. ET
by Ciara Linnane

All Dow stocks trading premarket are seeing red

All 29 of the Dow Jones Industrial Average components trading in the premarket are declining, as growing worries of a trade war with China has sent Dow futures tumbling. Only DowDuPont Inc.'s stock is still inactive ahead of the open. Among the biggest decliners, shares of Boeing Co. dropped 2.2%, Merck & Co. shed 2.1% and Caterpillar Inc. dropped 1.4%. The most-active stock is Apple Inc.'s , which fell 1.4%. Dow futures shed 269 points.

Apr. 6, 2018 at 7:57 a.m. ET
by Tomi Kilgore

Merck shares slide 1.5% premarket after news of failed drug trial

Apr. 6, 2018 at 7:36 a.m. ET
by Ciara Linnane

Incyte, Merck don't expect phase 3 study of melanoma treatment to meet 2nd endpoint

Apr. 6, 2018 at 7:34 a.m. ET
by Tomi Kilgore

Incyte, Merck said an external DMC determined study of melanoma treatment missed endpoint

Apr. 6, 2018 at 7:33 a.m. ET
by Tomi Kilgore

AstraZeneca submits drugs for U.S., Europe review

Update includes extra information, analyst sales forecast and updated share price AstraZeneca PLC (AZN.LN) said Tuesday that regulators in Europe and the U.S. have accepted applications for cancer treatments Lynparza and Moxetumomab Pasudotox. In the U.S., the Food and Drug Administration has accepted the biologics license application for Moxetumomab Pasudotox, the company said, adding that the treatment--which is used to treat adult patients with hairy-cell leukemia--has been granted priority-review status.

Apr. 3, 2018 at 10:36 a.m. ET
by MarketWatch.com

Intel, Amazon and Tesla lead tech stocks lower on the first trading day of April

Apr. 3, 2018 at 6:57 a.m. ET
by Philip van Doorn

Breaking

3M Co.'s stock has been the biggest drag on the Dow in the first quarter of 2018

The Dow Jones Industrial Average on Thursday was on track to snap a quarterly win streak, and the biggest contributor the end of that successful run has been 3M Co. Shares of 3M Co. have fallen 6.4%, sapping 129 points from the price-weighted index over the course of the first three months of 2018, according to WSJ Market Data Group. Boeing Co.' shares [: BA], meanwhile, the Dow's most influential component among its 30, by dint of its share price, was the biggest contributor to 121-year-old average in the first quarter, adding more than 170 points. That said, it was the biggest drag in the Dow's monthly performance, exacting a 290-point toll on the Dow, while shares of Merck & Co. provided the best lift for the month, 5 points. The Dow is set to decline 2% for the first three months of 2018, the S&P 500 index is set to fall 1% over the same stretch. Both benchmarks are on track to snap a streak of nine straight quarterly gains. For the month, the Dow is looking at a 3.3% drop in March, while the S&P 500 index is set to to fall 2.4%.

Mar. 29, 2018 at 3:02 p.m. ET
by Mark DeCambre

FDA push for cheaper ‘biosimilar’ drugs could challenge pharma’s biggest blockbusters

Mar. 29, 2018 at 12:06 p.m. ET
by Emma Court

Stocks to Watch: Leucadia, Caterpillar, Boeing, Merck, PayPal

Here are some of the companies with shares expected to trade actively in Monday's session.

Apr. 9, 2018 at 9:27 a.m. ET
on The Wall Street Journal

Biotech Gets a Reality Check

The drug industry has poured billions of dollars into novel drugs that fight cancer, generating significant value for biotech investors. It is a problem, then, when potential blockbuster drugs miss the mark.

Apr. 6, 2018 at 4:29 p.m. ET
on The Wall Street Journal

Incyte Shares Fall After Cancer Drug Fails in Trial With Merck’s Keytruda

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies.

Apr. 6, 2018 at 12:41 p.m. ET
on The Wall Street Journal

Stocks to Watch: Incyte, JPMorgan, Boeing, WageWorks

Companies with shares expected to trade actively in Friday's session include Incyte, JPMorgan, Boeing and WageWorks.

Apr. 6, 2018 at 9:30 a.m. ET
on The Wall Street Journal

Trump Policy Change Is a Win for Drugmakers

The Trump administration has issued a policy change that could drive up prices of certain biologic drugs, implementing a new industry-backed measure that overturns existing regulation that promoted lower prices.

Mar. 22, 2018 at 7:00 a.m. ET
on The Wall Street Journal

More Prison Inmates Get Access to Hepatitis-C Drugs

More prisoners with hepatitis C are becoming eligible for treatment with effective but costly drugs like Harvoni and Sovaldi from Gilead Sciences Inc., as a result of lawsuits filed by inmates in Massachusetts and Florida.

Mar. 9, 2018 at 4:36 p.m. ET
on The Wall Street Journal

J&J Says Discounts Cut the Prices for Its Drugs, Though Revenue Rose

Johnson & Johnson says its net drug prices overall fell last year due to discounts and rebates. Revenue still rose 6.7%

Mar. 8, 2018 at 6:23 p.m. ET
on The Wall Street Journal

Drug That Promises to Kill Flu in a Day Approved in Japan

Japan has approved a drug that its maker says can kill the flu virus in 24 hours, paving the way for what health experts believe could be a breakthrough in the way the illness is treated.

Feb. 23, 2018 at 7:00 a.m. ET
on The Wall Street Journal

Big Stock Buys in GE, Citi, DowDuPont, Merck

Pension manager Aimco bought 1.5 million more GE shares in Q4. It also sold most of its Pfizer stake.

Feb. 16, 2018 at 1:11 p.m. ET
on Barron's Online

White House Blames Russia For Massive 2017 Cyberattack

The White House blamed Russia for a massive cyberattack last year that crippled computer networks at multinational firms worldwide, vowing the hack would be met with “international consequences.”

Feb. 15, 2018 at 6:21 p.m. ET
on The Wall Street Journal

U.K. Says Russia Behind Cyberattack That Crippled Global Firms

British officials blamed Russia for last June’s massive “Petya” cyberattack, which crippled computer networks at multinational firms including FedEx, container-ship giant A.P. Moeller-Maersk and pharmaceutical firm Merck & Co.

Feb. 14, 2018 at 8:12 p.m. ET
on The Wall Street Journal

Pimco’s Big Buys: Apple, Intel, Merck, Pfizer, GE

The bond investor made some big equity bets in the fourth quarter. The Apple position was raised 10-fold.

Feb. 14, 2018 at 8:21 a.m. ET
on Barron's Online

3 Biotechs That Could Benefit From an M&A Frenzy

Two veteran Janus Henderson health-care managers talk about innovation and takeover potential in a dynamic sector.

Feb. 13, 2018 at 10:04 a.m. ET
on Barron's Online

Experimental Drug Promises to Kill the Flu Virus in a Day

As Americans suffer through the worst influenza outbreak in almost a decade, a Japanese drugmaker says it has developed a pill that can kill the virus within a day. But even if the experimental drug lives up to the claim, it likely won’t be available in the U.S. until next year at the earliest.

Feb. 10, 2018 at 7:00 a.m. ET
on The Wall Street Journal

Selling CVS, Chipotle, Costco and Qualcomm

D.A. Davidson chopped its Chipotle stake by more than 40%. It cut the Qualcomm investment by a third.

Feb. 9, 2018 at 8:31 a.m. ET
on Barron's Online

Why Sanofi and Rivals Are Paying Up for Deals

One of pharma’s most lucrative assets is starting to weaken. That helps explain the hot deals market.

Feb. 5, 2018 at 11:10 a.m. ET
on The Wall Street Journal

Stocks to Watch: Apple, Amazon, Alphabet, Visa, Sprint, Exxon, Mattel, Merck, Viacom

Among the companies with shares expected to trade actively in Friday's session are Apple, Amazon.com, Alphabet, Visa, Sprint, Mattel, Merck and Viacom.

Feb. 2, 2018 at 9:15 a.m. ET
on The Wall Street Journal

The Strong Case for Health-Care Spinoffs

Spinoffs and asset sales may benefit shareholders more than chasing growth in a frenzied health-care deals market.

Jan. 25, 2018 at 5:30 a.m. ET
on The Wall Street Journal

Stocks to Watch: Goldman, BofA, Juno Therapeutics, Ford, Alphabet, Boeing, CSX

Among the companies with shares expected to trade actively in Wednesday's session are Goldman Sachs, Bank of America, Juno Therapeutics, Ford Motor, Alphabet and Boeing.

Jan. 17, 2018 at 9:27 a.m. ET
on The Wall Street Journal

Stocks to Watch: Citigroup, GE, UnitedHealth, Apple, Alphabet, Amazon, Ford, Fiat Chrysler, GM, Merck

Among the companies with shares expected to trade actively in Monday's session are Citigroup Inc., General Electric Co., UnitedHealth Group Inc., Apple Inc., Alphabet Inc. and Amazon.com Inc.

Jan. 16, 2018 at 9:28 a.m. ET
on The Wall Street Journal

Other News
Press Releases

Merck Moves Ahead With Late-Stage Trial Win

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.

Apr. 9, 2018 at 9:21 a.m. ET
on 247WallSt.com

Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge

Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.

Apr. 9, 2018 at 9:48 a.m. ET
on Zacks.com

The Bio-Tech 'Wreck': General, And Company-Specific Analysis

Apr. 9, 2018 at 9:43 a.m. ET
on Seeking Alpha

3 Things In Biotech, April 8: Incyte's Crash, AbbVie's Coup, Mologen's Coming

Apr. 9, 2018 at 8:00 a.m. ET
on Seeking Alpha

Merck's Keytruda successful in late-stage study in first-line lung cancer; shares up 3% premarket

Apr. 9, 2018 at 7:34 a.m. ET
on Seeking Alpha

Biotech Analysis Central Pharma News: Allergan And Richter's Success, Sellas Life Sciences' Breast Cancer Data, Abbvie's Patent Boost

Apr. 9, 2018 at 3:10 a.m. ET
on Seeking Alpha

Incyte's Horrible News Derails a Promising Class of Cancer Drugs

Apr. 6, 2018 at 6:30 p.m. ET
on Motley Fool

Biotech Gets a Reality Check

Apr. 6, 2018 at 4:29 p.m. ET
on The Wall Street Journal

10 Safe Dividend Stocks for the Second Quarter

Apr. 6, 2018 at 3:08 p.m. ET
on InvestorPlace.com

Why Incyte and NewLink Genetics Crashed Today

Apr. 6, 2018 at 1:54 p.m. ET
on Motley Fool

ASLAN Pharmaceuticals Files For $86 Million U.S. IPO

Apr. 6, 2018 at 1:28 p.m. ET
on Seeking Alpha

Incyte Shares Fall After Cancer Drug Fails in Trial With Merck’s Keytruda

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies.

Apr. 6, 2018 at 12:41 p.m. ET
on The Wall Street Journal

Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure

Apr. 6, 2018 at 12:19 p.m. ET
on InvestorPlace.com

Incyte, Merck Fall on Failed Late-Stage Study

Apr. 6, 2018 at 12:05 p.m. ET
on GuruFocus.com

Biogen Cracks the Case With AbbVie for Humira Biosimilar

Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.

Apr. 6, 2018 at 11:06 a.m. ET
on Zacks.com

Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus

Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study

Apr. 6, 2018 at 10:11 a.m. ET
on Zacks.com

What Has Tanked Incyte and NewLink Genetics

Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.

Apr. 6, 2018 at 9:39 a.m. ET
on 247WallSt.com

Incyte epacadostat flop weighing on certain biotechs premarket

Apr. 6, 2018 at 8:48 a.m. ET
on Seeking Alpha

Incyte's epacadostat flunks late-stage melanoma study

Apr. 6, 2018 at 7:43 a.m. ET
on Seeking Alpha

Key events next week - healthcare

Apr. 6, 2018 at 7:14 a.m. ET
on Seeking Alpha

Global Respiratory Inhaler Market Opportunities 2018: Beximco Pharmaceuticals , PARI Medical Holding, H&T PRESSPART, Boehringer Ingelheim GmbH

Apr. 9, 2018 at 8:00 a.m. ET
on marketresearch.biz

Global Implantable Drug Delivery Devices Market Opportunities 2018: Psivida Corp, Arrow International, Theragenics Corporation, Bausch & Lomb

Apr. 9, 2018 at 7:30 a.m. ET
on marketresearch.biz

KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells

KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells

Apr. 9, 2018 at 6:45 a.m. ET
on BusinessWire - BZX

Acetaldehyde Market Size & Share | Global Research Report, 2023

Apr. 9, 2018 at 3:34 a.m. ET
on Financeswire

Global pulmonary drug delivery systems market growth is expected to be driven by rising incidence of respiratory disease/disorders globally

Apr. 9, 2018 at 2:04 a.m. ET
on marketresearch.biz

Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Apr. 6, 2018 at 7:30 a.m. ET
on BusinessWire - BZX

Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022 Featuring Astellas Pharma, Pfizer, Allergan, , Merck & Co., Mylan, Teva Pharma and Ferring Pharma - ResearchAndMarkets.com

Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022 Featuring Astellas Pharma, Pfizer, Allergan, , Merck & Co., Mylan, Teva Pharma and Ferring Pharma - ResearchAndMarkets.com

Apr. 6, 2018 at 5:49 a.m. ET
on BusinessWire - BZX

United States : The European Medicines Agency Accepts Regulatory Submission for LYNPARZA (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

Apr. 5, 2018 at 7:11 p.m. ET
on Euclid Tenders Info

United States : Merck Receives 2018 ENERGY STAR Sustained Excellence Award

Apr. 5, 2018 at 7:11 p.m. ET
on Euclid Tenders Info

Cybersecurity in Healthcare, 2018-2030

Apr. 5, 2018 at 2:42 p.m. ET
on PR Newswire - PRF

HCL Technologies Acquires Life Sciences and Consumer Services Provider C3i Solutions

Apr. 5, 2018 at 11:25 a.m. ET
on BusinessWire - BZX

Merck Manuals Survey: Medical Students Seek Global Health Experiences to Enhance their Education

Apr. 5, 2018 at 8:03 a.m. ET
on PR Newswire - PRF

Wired News - Merck and AstraZeneca Announced that EMA Will Review MAA for LYNPARZA(R) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

Apr. 5, 2018 at 7:40 a.m. ET
on ACCESSWIRE

Global precision medicine market is expected to be driven rising prevalence of cancer in next 10 years

Apr. 5, 2018 at 7:31 a.m. ET
on marketresearch.biz

Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Apr. 4, 2018 at 2:35 p.m. ET
on PR Newswire - PRF

Oncolytics Biotech(R) to Present at the MicroCap Conference

Apr. 4, 2018 at 10:42 a.m. ET
on Marketwired

Global Melanoma Therapeutics Market Opportunities 2018: AstraZeneca, Novartis AG, Ziopharm Oncology, Celgene Corporation

Apr. 4, 2018 at 8:10 a.m. ET
on marketresearch.biz

AVROBIO, Inc. Appoints Annalisa Jenkins to its Board of Directors

Apr. 4, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

PatientSafe Solutions Partners with ILÚM Health Solutions to Deploy Infectious Disease Notifications in the PatientTouch Platform

Apr. 4, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Drug Delivery System Market is Driven by Increasing Incidence of Chronic Disease Across Globe

Apr. 4, 2018 at 5:09 a.m. ET
on marketresearch.biz

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare Services. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the company or through joint ventures. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines, which it sells to veterinarians, distributors and animal producers. The Alliances segment includes revenue from the company relationship with AstraZeneca LP. The Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The company was founded in 1970 and is headquartered in Kenilworth, NJ. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 23 Full Ratings

Benzinga's Top Upgrades, Downgrades For April 5, 2018

Apr. 5, 2018 at 9:23 a.m. ET
on Benzinga.com

Analysts’ Recommendations for Johnson & Johnson in March 2018

Apr. 3, 2018 at 4:38 p.m. ET
on MarketRealist.com

What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy

Apr. 2, 2018 at 12:18 p.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Amgen Inc.	0.47%	$121.28B
GlaxoSmithKline PLC ADR	0.53%	$99.36B
Novartis AG ADR	0.66%	$211.54B
Bristol-Myers Squibb Co.	-2.91%	$99.54B
Johnson & Johnson	0.45%	$343.65B

Competitor Data Provided By

Dow	24,120.54	187.78	0.78%
S&P 500	2,625.02	20.55	0.79%
Nasdaq	7,001.79	86.68	1.25%
GlobalDow	3,014.14	13.55	0.45%
Gold	1,335.30	-0.80	-0.06%
Oil	63.12	1.06	1.71%

Merck & Co. Inc.

$ 55.05

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Merck's stock jumps 3.3% to pace the 28 of 30 Dow components trading higher

Merck's stock climbs 2.3% to pace Dow's premarket gainers after positive trial news

Merck's stock up 1.5% premarket after Keytruda trial meets primary endpoint

NewLink says its IDO inhibitors are different but will still conduct clinical program review

NewLink Genetics plans to review clinical programs after Merck, Incyte trial failure

Incyte shares fall 19% after resuming trade following a halt

Merck shares slide 1.5% premarket after news of failed drug trial

Incyte, Merck don't expect phase 3 study of melanoma treatment to meet 2nd endpoint

Incyte, Merck said an external DMC determined study of melanoma treatment missed endpoint

Stocks

Columns

Authors

Topics

^$ 55.05